Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Fudan University Shanghai Cancer Center · 81th Hospital of PLA · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
810
total citations
- FWCI
- 27.85
- Percentile
- 100%
- References
- 38
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Regorafenib
- Placebo
- Internal medicine
- Clinical endpoint
- Colorectal cancer
- Population
- Performance status
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.